CytoNiche Launches 3D FloTrix Experience Center in Singapore to Advance Affordable Stem Cell Therapies
Singapore, July 22, 2025 – CytoNiche Biotech, a leader in 3D cell mass production technology, has opened its 3D FloTrix Experience Center in Singapore. This milestone marks a key step in the company’s global expansion, showcasing the technology behind China’s first approved stem cell therapy, with costs estimated by the company to be a fraction of comparable Western therapies.
The high cost of stem cell therapies remains a global barrier. For example, stem cell therapy costs $1.55 million per treatment on the market, while China’s approved stem cell injection, approved in 2025, costs approximately 158,400 CNY (~$21,600) per course (source: company annual report). CytoNiche’s 3D FloTrix platform enables this cost reduction through GMP-grade dissolvable microcarriers and an automated 3D cell...
